• Contact
Thursday, May 8, 2025
Register
Login
European Press
Advertisement
  • News
  • Business
  • Tech
  • Sport
  • Health
  • Entertainment
  • Lifestyle
  • Video
No Result
View All Result
  • News
  • Business
  • Tech
  • Sport
  • Health
  • Entertainment
  • Lifestyle
  • Video
No Result
View All Result
European Press
No Result
View All Result

Datavant, Boehringer Ingelheim partner to enhance clinical development

5 May 2025
in Health
Reading Time: 2 mins read
A A
Datavant, Boehringer Ingelheim partner to enhance clinical development
ShareShareShareShareShare


Data sharing technology company Datavant has expanded its collaboration with pharmaceutical company Boehringer Ingelheim to support Boehringer’s real-world evidence initiatives. 
The extended collaboration aims to leverage Datavant’s privacy-preserving tokenization and data connectivity technologies to strengthen clinical development and initiate strategies across 75 additional clinical trials and multiple new molecular entities.
Through Datavant Connect, a platform that helps balance data utility with data privacy, Boehringer can adeptly explore and evaluate third-party data sources without moving or sharing underlying data.
By applying Datavant’s technology across a broad portfolio of trials and launches, Boehringer Ingelheim aims to increase the integration of real-world data into drug development.
Furthermore, teams will implement tokenization in a phased rollout to ensure seamless integration with Boehringer Ingelheim’s existing research infrastructure. 
Arnaub Chatterjee, general manager and president, life sciences, ecosystem and public sector for Datavant, said by enabling secure and efficient data linkage at scale, Boehringer Ingelheim is establishing a new benchmark for medical research. 
“This partnership exemplifies how technology can reshape healthcare and improve patient outcomes,” Chatterjee said in a statement. 
Paul Petraro, executive director and head of the real world evidence analytics center of excellence for Boehringer Ingelheim, said investment in real-world data underscores Boehringer Ingelheim’s commitment to using cutting-edge technologies to advance medical research. 
“By expanding this approach across more trials and commercial launches, we are positioned to drive more personalized and cost-effective treatments, ultimately transforming patient care,” Petraro said in a statement.
THE LARGER TREND  
In 2023, Socially Determined partnered with Datavant to provide life sciences companies with data on social risk drivers to improve health equity and patient outcomes.
Socially Determined uses data to offer insights into the social determinants of health, including factors like access to food, housing and transportation.
In 2021, psychedelic-inspired biotech company MindMed tapped Datavant to help link its clinical trial data with external evidence from other clinical trials and real-world data sources.
Using Datavant’s privacy-protecting technology, MindMed created datasets to understand the real-world treatment, service utilization and healthcare experiences of patients with psychiatric and substance use disorders. By increasing its data, MindMed hoped to better develop its product pipeline.
In 2020, Datavant closed $40 million in Series B funding. Transformation Capital led the raise, which saw contributions from new backers Johnson & Johnson Innovation – JJDC and Cigna Ventures and existing investors Roivant Sciences and Flex Capital.
In 2023, Boehringer Ingelheim and tech giant IBM teamed up to harness the power of generative AI and foundation models to further biologic drug discovery. 
The partnership leveraged IBM’s foundation model technologies, consisting of pre-trained, large-scale neural network architectures, to accelerate the identification of novel antibodies vital for therapeutic development.
That same year, Boehringer Ingelheim and digital therapeutic company Click Therapeutics initiated a clinical trial called CONVOKE Study, which evaluated prescription digital therapeutics as an adjunct treatment for schizophrenia.
The randomized trial included 432 participants and compared prescription digital therapeutics to the standard of care using antipsychotic therapy over the course of 16 weeks. 

Credit: Source link

Related Posts:

  • Datavant, Boehringer Ingelheim partner to enhance clinical development
    Datavant, Boehringer Ingelheim partner to enhance…
  • Brainomix secures $18M to enhance stroke and lung fibrosis treatment
    Brainomix secures $18M to enhance stroke and lung…
  • MedeAnalytics, Socially Determined, Mathematica join forces
    MedeAnalytics, Socially Determined, Mathematica join forces
  • Flatiron Health, Massive Bio partner to improve clinical trial access
    Flatiron Health, Massive Bio partner to improve…
ShareTweetSendPinShare
Previous Post

Malta’s golden passport scheme rejected by EU top court

Next Post

Nintendo Switch 2 preorder guide: Price, release date, restocks

Next Post
Nintendo Switch 2 preorder guide: Price, release date, restocks

Nintendo Switch 2 preorder guide: Price, release date, restocks

Recommended

Overseas buyers line up to hear pitches from small UK exporters at new government roadshow

Overseas buyers line up to hear pitches from small UK exporters at new government roadshow

28 April 2025
PHL stocks end lower after last-minute selloff

PHL stocks end lower after last-minute selloff

28 April 2025
Knicks finally make Celtics statement in Game 1 win

Knicks finally make Celtics statement in Game 1 win

6 May 2025
Blue Shield of California shared private health data of 4.7M members with Google for years

Blue Shield of California shared private health data of 4.7M members with Google for years

24 April 2025
Latest news bulletin | April 4th – Morning

Latest news bulletin | April 4th – Morning

9 April 2025
European Press

European-press.com shares the latest news from Europe and around the world. It covers topics such as business, technology, sports, health, entertainment, and lifestyle. Feel free to get in touch with us!

Disclaimer  Privacy Policy – EU  Imprint 

Contact Us

What’s New Here!

  • ‘Romantasy’ ball blasted as epic scam: ‘Fyre Festival of BookTok’
  • Kremlin announces Ukraine ceasefire to coincide with World War II ‘Victory Day’
  • Rory McIlroy moving to UK with wife, daughter after US Open
  • Salmon Scotland urges further talks to scrap 10% US tariff after UK-US trade deal

Subscribe to Our Newsletter

Copyright 2025 © EUROPEAN PRESS All rights on our posts reserved!

Translate »
European Press
Manage Cookie Consent
To provide the best experiences, we use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us to process data such as browsing behaviour or unique IDs on this site. Not consenting or withdrawing consent, may adversely affect certain features and functions.
Functional Always active
The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.
Preferences
The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.
Statistics
The technical storage or access that is used exclusively for statistical purposes. The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.
Marketing
The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.
Manage options Manage services Manage {vendor_count} vendors Read more about these purposes
View preferences
{title} {title} {title}
No Result
View All Result
  • News
  • Business
  • Tech
  • Sport
  • Health
  • Entertainment
  • Lifestyle
  • Video

Copyright 2025 © EUROPEAN PRESS All rights on our posts reserved!

Are you sure want to unlock this post?
Unlock left : 0
Are you sure want to cancel subscription?
×